Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.43 |
| ▸ | WNT3A | P56704 | 4/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493438 | 0.80 | LMNA (0.57) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL10720268 | 0.77 | LMNA (0.60) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL27809181 | 0.77 | LMNA (0.50) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL28634751 | 0.76 | LMNA (0.64) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL14127342 | 0.76 | LMNA (0.53) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL746794 | 0.76 | LMNA (0.64) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL2195147 | 0.74 | LMNA (0.62) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL10911221 | 0.74 | LMNA (0.52) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL10911687 | 0.74 | LMNA (0.52) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL221518 | 0.74 | LMNA (0.62) | LMNAGAACNR2CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-0856024-B1 | POLYMERISABLE COMPOSITION AND POLYMERISATION METHOD | CIBA SC HOLDING AG (CH) | 2003-11-19 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-0771830-B1 | Curable composition containing cycloolefins, silane and filler | CIBA SC HOLDING AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| EP-0839821-B1 | Process for preparing catalysts | CIBA SC HOLDING AG (CH) | 2002-11-20 | — | — | EP | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6323295-B1 | AS POLYMERIZATION CATALYST FOR METATHESIS POLYMERIZATION AND HOMO- AND COPOLYMERS CONTAINING RECURRING STRUCTURAL EMBODIMENTS WITH STRAINED CYCLOALKENYL RADICALS BONDED TO MONOMER UNITS VIA BIVALENT BRIGE GROUPS | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-11-27 | — | — | US | disclosed |
| WO-2001083569-A1 | CATALYST COMPOUNDS, CATALYST SYSTEMS AND THEIR USE IN A POLYMERIZATION PROCESS | UNIVATION TECHNOLOGIES, LLC (US) | 2001-11-08 | — | — | WO | disclosed |
| US-6281307-B1 | METATHESIS POLYMERIZATION | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-08-28 | — | — | US | disclosed |
| EP-0799266-A1 | POLYMERISABLE COMPOUND AND A POLYMERISATION PROCESS | Ciba SC Holding AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1997032913-A1 | POLYMERIZABLE COMPOSITION | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1997-09-12 | — | — | WO | disclosed |
| EP-0792252-A1 | MONOMERS AND COMPOSITION WHICH CAN BE CROSSLINKED AND CROSSLINKED POLYMERS | Ciba SC Holding AG (CH) | 1997-09-03 | — | — | EP | disclosed |
| EP-0792307-A1 | POLYMERIZABLE COMPOSITION AND PROCESS FOR POLYMERIZING CYCLICAL OLEFINS | Ciba SC Holding AG (CH) | 1997-09-03 | — | — | EP | disclosed |
| EP-0771830-A2 | Curable composition containing cycloolefins, silane and filler | Ciba SC Holding AG (CH) | 1997-05-07 | — | — | EP | disclosed |
| WO-1997014738-A1 | POLYMERISABLE COMPOSITION AND POLYMERISATION METHOD | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1997-04-24 | — | — | WO | disclosed |
| WO-1996023829-A1 | POLYMERISABLE COMPOSITION, PROCESS FOR PRODUCING CROSS-LINKED POLYMERS, AND CROSS-LINKABLE POLYMERS | CIBA SPECIALTY CHEMICALS INC. (CH) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996020235-A1 | POLYMERISABLE COMPOUND AND A POLYMERISATION PROCESS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1996-07-04 | — | — | WO | disclosed |
| WO-1996016103-A1 | POLYMERIZABLE COMPOSITION AND PROCESS FOR POLYMERIZING CYCLICAL OLEFINS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996016008-A1 | MONOMERS AND COMPOSITION WHICH CAN BE CROSSLINKED AND CROSSLINKED POLYMERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | LMNA 1519/4885GAA 3055/4885CNR2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.